After all, the prospects for Gene Editing Technology are simply too vast. Not to mention anything else, the medical industry alone has a market size of trillions of dollars.
At this time, the key core technology patents were in the hands of Xingtu Gene Company. How could those global capitals not be extremely envious?
Of course, while global capital may be envious of Xingtu Gene Company is ultimately a company of Great Xia, and Great Xia has always been a very special country.
Therefore, although global capital might want to swallow Xingtu Gene Company whole through overt and covert means, it can only act according to the rules under the constraints of Great Xia.
This is also an intangible benefit of having the Great Xia Kingdom as a backer.
If Xingtu Gene Company were a company from a small Southeast Asian country, or even from South Korea or Japan, it would definitely be devoured by global capital.
After all, the overseas world is ultimately a world where capital and strength reign supreme, even though with the advent of the internet age, global capitalists have become more restrained in their actions.
But which rise of capital has not been stained with the blood of innocent people?
Therefore, if Xingtu Gene Company is an overseas company, it would lack the support of official, underground, and overt power.
That would have been unsustainable, and the economy wouldn't have developed to its current state.
Of course, when faced with profits of trillions of dollars, no matter how strong one's strength is overseas, it is all in vain. When facing global capital, one will ultimately have to sacrifice one's own flesh to feed the eagle.
However, Xingtu Gene Company is ultimately not a company from overseas countries, but a company from the Great Xia Kingdom.
If they want to target Lin Feng and Xingtu Gene Company, they will ultimately have to go through the Great Xia Kingdom, so they can't do anything to Xingtu Gene Company.
Thus, Xingtu Gene Company unwittingly escaped a fatal disaster, which can be considered an unexpected blessing.
Of course, although overseas capital cannot seize it by force, they will not give up when faced with a market size of trillions of dollars.
Therefore, as global capital was activated by the Gene Editing Technology craze, a wave of investment swept the world.
This investment boom is only slightly less intense than the internet investment boom of yesteryear, and can be described as quite fierce.
Among these companies, all those related to Gene Editing Technology received offers for equity investment and financing.
Even medical and pharmaceutical companies unrelated to Gene Editing Technology have benefited from this frenzied wave of capital investment.
Well-known pharmaceutical giants Johnson & Johnson & Johnson, Pfizer, Novartis, Sanofi, GSK...
The market value of all established healthcare companies surged by 15% to 30% in just a few days, truly skyrocketing.
Clearly, global stock market investors believe that with the decades or even centuries of experience these established companies have built, they are sure to be among the ultimate winners in this new wave of Gene Editing Technology.
Therefore, those savvy individuals rushed to enter the market early, snapping up shares of established pharmaceutical companies in hopes of getting a piece of the pie.
Of course, compared to established pharmaceutical companies, the Broad Institute and the Max Planck Institute, which hold core technology patents, are the focus of global capital attention.
After all, core technology patents are the backbone of a company; otherwise, no matter how big your factory is or how many workers you have, you're just a contract manufacturer.
As a result, the doors of the Max Planck Institute and the Broad Institute were constantly being opened to them, with countless companies contacting them.
Among them, Church, the director of the Broad Institute, is also very good at manipulating current events. So, under the pre-arranged methods that Church and Zhang Feng had discussed beforehand.
Broad Institute Director Church publicly announced that Zhang Feng of the Broad Institute had made a major breakthrough in Gene Editing Technology.
The video footage released by the Broad Institute uses a series of detailed data and parameters to prove that the Broad Institute has successfully eradicated SIV Monkey Immunodeficiency Virus!
In other words, the research and development progress of the Broad Institute seems to have reached the level of the EBT-001 gene therapy drug originally developed by Xingtu Gene Company.
Under these circumstances, the Broad Institute seems to be getting closer to the EBT-002 gene therapy drug.
As people began to think this way, companies eager to invest in the Broad Institute became even more enthusiastic and excited.
Of course, the actions of Broad Institute Director Church did not stop there. After announcing the successful eradication of SIV Monkey Immunodeficiency Virus.
Broad Institute Director Church publicly declared that after successfully eliminating SIV Monkey Immunodeficiency Virus), Zhang Feng was fully confident in how to solve the human AIDS virus.
Broad Institute Director Church boasted that they would be able to crack the AIDS virus in less than a month, and then take the opportunity to apply for human trials!
In response, Broad Institute Director Church's words were like adding a bucket of gasoline to a burning fire.
Under these circumstances, the Broad Institute successfully became the center of public opinion and the epicenter of the global investment boom, at which point the Broad Institute could naturally reap the rewards.
In the end, it only took a week for the Broad Institute to publicly announce that it had received a huge investment of $35 billion!
Of course, no matter how much investment funds are received, it is ultimately just a string of numbers. What netizens care more about are the investment companies behind it.
Among the companies that have received these investments are global pharmaceutical giants and various well-known investment firms on Wall Street.
Among them are pharmaceutical giants such as Johnson & Johnson & Johnson, Pfizer, Novartis, Sanofi, and GSK...
As for the various well-known investment companies on Wall Street, there are dozens of them. It can be said that every well-known investment company has invested in the Broad Institute.
Faced with this situation, people knew that the Broad Institute was about to make a name for itself.
Because the investments made by those pharmaceutical giants and Wall Street Capital bring not only money, but also a variety of other intangible benefits.
From now on, whatever the Broad Institute does will go smoothly and everything will go well.
Of course, we're not talking about those abstract things, but rather the real, tangible benefits.
By forming alliances with those global pharmaceutical giants, these pharmaceutical giants will then partner with gene-editing companies controlled by Wall Street Capital.
It is estimated that they will also send their own researchers to join the Broad Institute, attempting to get a share of the pie and gain more say.
As for the Broad Institute's opinion on this matter?
They naturally wouldn't object to others adding their own materials, after all, they are just a research and development institution and don't have their own factory.
Therefore, Church was overjoyed to accept all the offers of support from others to researchers.
With the support of this group of experienced and talented researchers, the Broad Institute's confidence in quickly bringing the 'Viral Transduction Method' to practical application has greatly increased.
Thus, through this series of well-prepared moves, the Broad Institute became a leader in this wave of capital investment and one of the biggest winners.
This will also bring certain potential risks to Xingtu Gene Company, after all, two tigers cannot share one mountain.
At this time, the Broad Institute already had Zhang Feng, a genius in the field of gene editing, and Church was ruthless, preparing to use the lives of people in backward areas to quickly advance scientific research results.
Now, there is a massive cash flow of $35 billion to support this, plus research personnel support from pharmaceutical giants and pharmaceutical companies controlled by Wall Street Capital...
With the combined efforts of all parties, they may indeed be able to catch up with Xingtu Gene Company's current research and development progress within one or two years.
This will allow the 'Viral Transduction Method technology route' to be practically implemented, just like the current 'RNP Complex Technology Pathway'.
If they really manage to do this, even with some potential risks, as long as they achieve the basic goal of editing the genes of cells throughout the body, it will be worthwhile.
Therefore, the value of the technology patents held by Xingtu Gene Company will inevitably plummet.
Finally, given that the Broad Institute is backed by a consortium of pharmaceutical giants, it will be even more difficult for Xingtu Gene Company to compete with these giants for a share of the medical market.
After all, when people are sick and need treatment, they will definitely give priority to well-known century-old pharmaceutical giants.
After all, Xingtu Gene Company that has only been established for a few years, has too low a reputation and level of trust, and is not people's first choice.